Autor(en)
Maertens, J; Cesaro, S; Maschmeyer, G; Einsele, H; Donnelly, J.P; Alanio, A; Hauser, P.M; Lagrou, K; Melchers, W.J.G; Helweg-Larsen, J; Matos, O; Bretagne, S; Cordonnier, C; Bruggemann, R.J.M; Kullberg, B.J; et al
Titel
ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients
Teil von
  • Journal of antimicrobial chemotherapy, 2016, Vol.71 (9), p.2397-404
Ort / Verlag
OXFORD: OXFORD UNIV PRESS
Links zum Volltext
Quelle
Web of Science
Beschreibungen
The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults ( A-II: ) and children ( A-I: ) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen ( B-II: ). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX
Die Universität der Informationsgesellschaft